B-intervention	0	11	Dexrazoxane
O	12	20	protects
O	21	27	breast
O	28	34	cancer
O	35	43	patients
O	44	48	with
O	49	57	diabetes
O	58	62	from
B-condition	63	75	chemotherapy
I-condition	75	76	-
I-condition	76	83	induced
I-condition	84	98	cardiotoxicity
O	98	99	.

O	100	102	To
O	103	111	evaluate
O	112	115	the
O	116	132	cardioprotective
O	133	139	effect
O	140	142	of
O	143	154	dexrazoxane
O	155	156	(
O	156	159	DEX
O	159	160	)
O	161	163	on
O	164	176	chemotherapy
O	177	179	in
O	180	188	patients
O	189	193	with
B-eligibility	194	200	breast
I-eligibility	201	207	cancer
I-eligibility	208	212	with
I-eligibility	213	223	concurrent
I-eligibility	224	228	type
I-eligibility	229	230	2
I-eligibility	231	239	diabetes
I-eligibility	240	248	mellitus
I-eligibility	249	250	(
I-eligibility	250	253	DM2
I-eligibility	253	254	)
O	254	255	.

B-total-participants	256	262	Eighty
O	263	269	female
O	270	278	patients
O	279	283	with
O	284	290	breast
O	291	297	cancer
O	298	302	with
O	303	306	DM2
O	307	311	were
O	312	320	randomly
O	321	329	assigned
O	330	332	to
O	333	340	receive
B-control	341	353	chemotherapy
I-control	354	358	only
O	359	361	or
O	362	374	chemotherapy
O	375	379	plus
O	380	383	DEX
O	383	384	.

O	385	388	All
O	389	397	patients
O	398	406	received
O	407	409	80
O	410	412	mg
O	412	413	/
O	413	414	m
O	415	425	epirubicin
O	426	429	and
O	430	433	500
O	434	436	mg
O	436	437	/
O	437	438	m
O	439	455	cyclophosphamide
O	456	458	by
O	459	470	intravenous
O	471	479	infusion
O	480	485	every
O	486	487	3
O	488	493	weeks
O	494	497	for
O	498	499	a
O	500	505	total
O	506	508	of
O	509	510	6
O	511	517	cycles
O	517	518	.

O	519	522	The
O	523	528	group
O	529	537	assigned
O	538	540	to
O	541	548	receive
O	549	561	chemotherapy
O	562	567	alone
O	568	576	received
O	577	584	placebo
O	585	587	30
O	588	595	minutes
O	596	602	before
O	603	613	epirubicin
O	614	628	administration
O	628	629	.

O	630	633	The
O	634	639	group
O	640	648	assigned
O	649	651	to
O	652	659	receive
O	660	672	chemotherapy
O	673	677	plus
O	678	681	DEX
O	682	690	received
O	691	694	800
O	695	697	mg
O	697	698	/
O	698	699	m
O	700	703	DEX
O	704	706	30
O	707	714	minutes
O	715	721	before
O	722	732	epirubicin
O	733	747	administration
O	747	748	.

O	749	756	Cardiac
O	757	765	function
O	766	769	and
O	770	780	hematology
O	781	787	before
O	788	791	and
O	792	797	after
O	798	799	6
O	800	806	cycles
O	807	809	of
O	810	822	chemotherapy
O	823	827	were
O	828	836	analyzed
O	836	837	.

O	838	843	There
O	844	847	was
O	848	850	no
O	851	861	difference
O	862	864	in
B-outcome	865	873	baseline
I-outcome	874	881	systole
I-outcome	882	884	or
I-outcome	885	893	diastole
I-outcome	894	902	function
O	903	910	between
O	911	914	the
O	915	916	2
O	917	920	DM2
O	921	927	groups
O	927	928	.

O	929	937	Patients
O	938	947	receiving
O	948	960	chemotherapy
O	961	966	alone
O	967	978	experienced
O	979	992	significantly
O	993	1000	greater
B-outcome	1001	1011	reductions
I-outcome	1012	1014	in
I-outcome	1015	1017	Ea
O	1018	1021	and
O	1022	1035	significantly
O	1036	1043	greater
B-outcome	1044	1054	elevations
I-outcome	1055	1057	in
I-outcome	1058	1059	E
I-outcome	1059	1060	/
I-outcome	1060	1062	Ea
I-outcome	1063	1066	and
I-outcome	1067	1070	Tei
I-outcome	1071	1076	index
O	1077	1079	in
O	1080	1090	comparison
O	1091	1095	with
O	1096	1104	patients
O	1105	1114	receiving
O	1115	1127	chemotherapy
O	1128	1132	plus
O	1133	1136	DEX
O	1136	1137	.

O	1138	1143	After
O	1144	1156	chemotherapy
O	1156	1157	,
B-outcome	1158	1168	superoxide
I-outcome	1169	1178	dismutase
O	1179	1182	was
O	1183	1196	significantly
O	1197	1204	reduced
O	1204	1205	,
O	1206	1209	and
O	1210	1215	serum
O	1216	1231	malondialdehyde
O	1232	1233	(
O	1233	1236	MDA
O	1236	1237	)
O	1238	1241	was
O	1242	1255	significantly
O	1256	1265	increased
O	1266	1268	in
O	1269	1277	patients
O	1278	1282	with
O	1283	1286	DM2
O	1286	1287	.

B-outcome	1288	1293	Serum
I-outcome	1294	1304	superoxide
I-outcome	1305	1314	dismutase
I-outcome	1315	1321	levels
O	1322	1326	were
O	1327	1337	comparable
O	1338	1345	between
O	1346	1349	the
O	1350	1351	2
O	1352	1358	groups
O	1359	1365	before
O	1366	1369	and
O	1370	1375	after
O	1376	1388	chemotherapy
O	1388	1389	,
O	1390	1393	MDA
O	1394	1400	levels
O	1401	1405	were
O	1406	1416	comparable
O	1417	1424	between
O	1425	1428	the
O	1429	1430	2
O	1431	1437	groups
O	1438	1444	before
O	1445	1457	chemotherapy
O	1457	1458	,
O	1459	1466	whereas
O	1467	1472	serum
O	1473	1476	MDA
O	1477	1480	was
O	1481	1494	significantly
O	1495	1501	higher
O	1502	1507	after
O	1508	1520	chemotherapy
O	1521	1523	in
O	1524	1527	the
O	1528	1540	chemotherapy
O	1541	1546	alone
O	1547	1552	group
O	1553	1555	in
O	1556	1566	comparison
O	1567	1571	with
O	1572	1575	the
O	1576	1581	group
O	1582	1586	that
O	1587	1595	received
O	1596	1599	DEX
O	1599	1600	.

O	1601	1604	DEX
O	1605	1613	protects
O	1614	1621	against
O	1622	1636	cardiotoxicity
O	1637	1644	induced
O	1645	1647	by
O	1648	1660	chemotherapy
O	1661	1663	in
O	1664	1672	patients
O	1673	1677	with
O	1678	1684	breast
O	1685	1691	cancer
O	1692	1696	with
O	1697	1707	concurrent
O	1708	1711	DM2
O	1711	1712	.
